Proffered Paper - Translational research

LINK to Proffered Paper - Translational research

LINK to STREAM (needs an ESMO registration)

1928O - Meta-analysis of tumour and T cell intrinsic mechanisms of sensitization to checkpoint inhibition

The abstract concludes: We find that high clonal mutation burden, apobec/UV/tobacco mutation signatures, together with elevated CXCL9 and CXCL13 expression, as core features marking a tumor as likely to respond to CPI therapy. As biomarker datasets continue to grow in size there is tangible opportunity to build a more complete understanding of CPI response, and identify molecularly defined patient cohorts with high chance of response.


1929O - Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients

The abstract concludes: Composite risk models based on blood parameters featuring the tumor-host interaction might provide non-invasive prognostic and predictive scores in ICI-treated advanced NSCLC patients.


1930O - Genomic alterations in solid tumours according to ESMO scale for clinical actionability of molecular targets (ESCAT)

The abstract concludes: ESCAT classification of genomic alterations is attainable in clinical practice through MTB and helps adjusting treatment on both standard of care or investigational settings. Since ESCAT tiers update regularly, a dynamic review of therapeutic choices is advised.


82O - Genomic evolution of metastatic tumours under therapeutic pressure

The abstract concludes: Our data demonstrates that a one-time WGS analysis during the disease course of a patient with metastatic cancer is (i) sufficient for identifying standard-of-care genomic biomarkers, and (ii) supportive of revealing investigational therapeutic targets that remain present at later stages of the disease.


1189O - Validation of whole genome sequencing in routine clinical practice

The abstract concludes: Based on the first 600 patients of the WIDE study, cWGS was found to be clinically feasible in routine molecular diagnostics in a comprehensive cancer center setting and has added value by providing additional treatment options for the majority of patients.